Dossier assessment
Trastuzumab deruxtecan (breast cancer) – Benefit assessment according to §35a Social Code Book V
Report documents
-
Extract of dossier assessment
Trastuzumab deruxtecan (breast cancer) – Benefit assessment according to §35a Social Code Book V
-
Dossier assessment
Trastuzumab deruxtecan (breast cancer) – Benefit assessment according to §35a Social Code Book V
Dossier assessment
Adults with unresectable or metastatic HER2-low breast cancer who have received prior chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy
- Patients with visceral disease: hint of considerable added benefit
- Patients without visceral disease: hint of major added benefit
Press releases
Trastuzumab deruxtecan: advantages also in HER2-low breast cancer
Additional information
Federal Joint Committee (G-BA)
2023-07-20 A G-BA decision was published.
Project details
- Project no.
- A23-07
- Commission
- Commission awarded on 01.02.2023 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Cancer
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.
Connected Projects
-
Dossier assessment
Trastuzumab deruxtecan (breast cancer, HER2+, at least 2 prior therapies) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Trastuzumab deruxtecan (breast cancer) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Trastuzumab deruxtecan (gastric cancer) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Addendum
Trastuzumab deruxtecan (breast cancer) – Addendum to Commission A23-07
Status: Commission completed
-
Dossier assessment
Trastuzumab deruxtecan (breast cancer) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Trastuzumab deruxtecan (gastric or gastroesophageal junction adenocarcinoma) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Trastuzumab deruxtecan (NSCLC) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed